Ovid Therapeutics Inc.OVIDNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank36
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-585.20%
↑ 80% vs avg
Percentile
P36
Within normal range
Streak
2 yr
Consecutive growthExpanding
Average
-2952.41%
Historical baseline
PeriodValueYoY Change
2025-585.20%+94.3%
2024-10207.07%+29.8%
2023-14544.13%-303.5%
2022-3604.47%-6135.6%
202159.72%+109.3%
2020-642.96%-
20190.00%-
20180.00%-
20170.00%-
20160.00%-